Loading stock data…
Minerva Neurosciences, Inc (NERV)
$5.43+1.06 (+24.26%)
Market ClosedLast close Jun 29
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Minerva Neurosciences, Inc. in the Healthcare sector is trading at $5.43 with a market capitalization of $218M. Wall Street consensus targets $9.50 (3 analysts), implying a +75.0% move over the next 12 months. The stock is currently 56% below its 52-week high of $12.46, remaining 14.6% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +75.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$16.67M↓ | -$4.98M↓ | -$2.84M↑ | -$3.37M↑ | -$3.90M |
| Net Income | -$125.40M↑ | -$283.67M↓ | -$2.74M↑ | -$3.26M↑ | -$3.75M |
Peer Comparison
JNJUNHPFE
Fundamentals
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$218.04M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.10
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
163.41%
Volume
Today's trading volume
377,008
Recent News
All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy
Minerva Neurosciences (NERV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Minerva Neurosciences (NERV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Minerva Neurosciences Touts Roluperidone Data, FDA-Aligned Trial Plan for Schizophrenia Symptoms
Minerva Neurosciences (NASDAQ:NERV) provided an update on its development program for roluperidone, which the company described as a potential first treatment option aimed at the negative symptoms of schizophrenia—an area where management has historically lagged behind treatments for positive sympto
Minerva Neurosciences: Q4 Earnings Snapshot
BURLINGTON, Mass. AP) — Minerva Neurosciences Inc. NERV) on Wednesday reported a loss of $283.7 million in its fourth quarter.
Institutions profited after Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap rose US$27m last week but individual investors profited the most
Key Insights Minerva Neurosciences' significant individual investors ownership suggests that the key decisions are...